Immunological insights into why pertussis continues to be endemic
Open Access
- 30 June 2026
- journal article
- review article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 22 (1) , 2692306
Abstract
Pertussis (whooping cough) is a vaccine-preventable bacterial disease caused by Bordetella pertussis. Despite widespread vaccination, cases have increased globally since the 1990s, with notable outbreaks in 2012, 2016, and following the COVID-19 pandemic. Persistent endemicity and periodic epidemics are driven by limited prevention of nasal colonization, waning immunity after vaccination or natural infection, and pathogen adaptation. Differences between acellular (aP) and whole-cell (wP) vaccines reflect distinct immune profiles, with aP vaccines favoring Th2 responses and wP vaccines inducing Th1/Th17 responses and tissue-resident memory T cells. Circulating strains have evolved under vaccine pressure, including shifts in ptxP, ptxA and prn alleles, increasing pertussis toxin production, emergence of pertactin-deficient variants, and rising macrolide resistance linked to 23S rRNA mutations. Optimizing current vaccine strategies and developing next-generation vaccines that improve durable, Th1/Th17-polarized immunity and reduce transmission are essential for enhanced pertussis control.Keywords
Funding Information
- Sanofi
This publication has 118 references indexed in Scilit:
- Protective Immunity to Bordetella pertussis Requires Both B Cells and Cd4+ T Cells for Key Functions Other than Specific Antibody ProductionJournal of Experimental Medicine, 2000
- Variation in the Bordetella pertussis Virulence Factors Pertussis Toxin and Pertactin in Vaccine Strains and Clinical Isolates in FinlandInfection and Immunity, 1999
- Polymorphism in the Bordetella pertussis Virulence Factors P.69/Pertactin and Pertussis Toxin in The Netherlands: Temporal Trends and Evidence for Vaccine-Driven EvolutionInfection and Immunity, 1998
- Role of gamma interferon in natural clearance of Bordetella pertussis infectionInfection and Immunity, 1997
- Mechanisms of immunity to the respiratory pathogen Bordetella pertussis in normal and gene knockout mice: clearance of primary infection is not enhanced by therapeutic interleukin-12Biochemical Society Transactions, 1997
- Interleukin-12 is produced by macrophages in response to live or killed Bordetella pertussis and enhances the efficacy of an acellular pertussis vaccine by promoting induction of Th1 cellsInfection and Immunity, 1996
- Pertussis caused by an erythromycin-resistant strain of Bordetella pertussisThe Pediatric Infectious Disease Journal, 1995
- Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection modelInfection and Immunity, 1993
- Uptake and intracellular survival of Bordetella pertussis in human macrophagesInfection and Immunity, 1992
- Enzyme-linked immunosorbent assay for detection of pertussis immunoglobulin A in nasopharyngeal secretions as an indicator of recent infectionJournal of Clinical Microbiology, 1981